Understanding the Market | TYK MEDICINES-B rose nearly 7% in the morning as the company announced multiple positive clinical data for CDK inhibitors at the ESMO annual meeting
TYK MEDICINES-B's stock price rose nearly 7% in the morning, and as of the time of writing, it has increased by 5.82%, trading at HKD 15.08, with a transaction volume of HKD 73.088 million. The company presented early clinical research results for three CDK inhibitors, namely TYK-00540, TY-2699a, and TY-302, at the 2025 ESMO annual meeting. Additionally, the key Phase II clinical trial of Aito tablets for non-small cell lung cancer has also attracted significant attention, with an application for market approval expected to be submitted in the fourth quarter of 2025
According to Zhitong Finance APP, TYK MEDICINES-B (02410) rose nearly 7% in the morning, and as of the time of publication, it was up 5.82%, trading at HKD 15.08, with a transaction volume of HKD 73.088 million.
On the news front, TYK MEDICINES previously announced that the company's board of directors is pleased to announce that the early clinical research results of three drugs in the field of cyclin-dependent kinase inhibitors (CDKi) that it is focusing on—TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i)—will be presented in poster form at the 2025 ESMO Annual Meeting. The ESMO 2025 Annual Meeting will be held from October 17 to 21 in Berlin, Germany.
It is worth noting that at the World Lung Cancer Conference in September 2025, the key Phase II clinical trial of Aituzhining tablets for brain metastases of non-small cell lung cancer released by TYK MEDICINES attracted significant attention from peers. It is reported that Aituzhining tablets (TY-9591) are highly selective small molecule inhibitors developed by TYK MEDICINES targeting classic EGFR mutations. The company completed the enrollment of 224 patients for conditional approval in November 2024 and submitted a Pre-NDA application in April 2025, with the formal submission of a conditional NDA application expected in the fourth quarter of 2025
